Amgen Announces Second Round of Refunds this Year for 340B Overcharges

Biotech company Amgen said last week it would pay refunds for 340B overcharges occurring in the third and fourth quarters of 2019.

The posting on the U.S. Health Resources and Services Administration website marks Amgen’s second 340B refund notice so far this year. The first was in May. Products include Amgen’s blockbuster rheumatoid arthritis therapy Enbrel ($4.4 billion in U.S. sales in 2021), neutropenia drug Neulasta ($1.5 billion), cholesterol treatment Repatha ($557 million), anemia drug Epogen ($521 million), cancer drug Kyprolis ($736 million) and anemia therapy Aranesp ($537 million).